Virtual histology of Alzheimer's disease: Biometal entrapment within amyloid-β plaques allows for detection via X-ray phase-contrast imaging.


Journal

Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144

Informations de publication

Date de publication:
15 10 2023
Historique:
received: 30 03 2023
revised: 21 07 2023
accepted: 25 07 2023
medline: 9 10 2023
pubmed: 14 8 2023
entrez: 13 8 2023
Statut: ppublish

Résumé

Amyloid-β (Aβ) plaques from Alzheimer's Disease (AD) can be visualized ex vivo in label-free brain samples using synchrotron X-ray phase-contrast tomography (XPCT). However, for XPCT to be useful as a screening method for amyloid pathology, it is essential to understand which factors drive the detection of Aβ plaques. The current study was designed to test the hypothesis that Aβ-related contrast in XPCT could be caused by Aβ fibrils and/or by metals trapped in the plaques. Fibrillar and elemental compositions of Aβ plaques were probed in brain samples from different types of AD patients and AD models to establish a relationship between XPCT contrast and Aβ plaque characteristics. XPCT, micro-Fourier-Transform Infrared spectroscopy and micro-X-Ray Fluorescence spectroscopy were conducted on human samples (one genetic and one sporadic case) and on four transgenic rodent strains (mouse: APPPS1, ArcAβ, J20; rat: TgF344). Aβ plaques from the genetic AD patient were visible using XPCT, and had higher β-sheet content and higher metal levels than those from the sporadic AD patient, which remained undetected by XPCT. Aβ plaques in J20 mice and TgF344 rats appeared hyperdense on XPCT images, while they were hypodense with a hyperdense core in the case of APPPS1 and ArcAβ mice. In all four transgenic strains, β-sheet content was similar, while metal levels were highly variable: J20 (zinc and iron) and TgF344 (copper) strains showed greater metal accumulation than APPPS1 and ArcAβ mice. Hence, a hyperdense contrast formation of Aβ plaques in XPCT images was associated with biometal entrapment within plaques. STATEMENT OF SIGNIFICANCE: The role of metals in Alzheimer's disease (AD) has been a subject of continuous interest. It was already known that amyloid-β plaques (Aβ), the earliest hallmark of AD, tend to trap endogenous biometals like zinc, iron and copper. Here we show that this metal accumulation is the main reason why Aβ plaques are detected with a new technique called X-ray phase contrast tomography (XPCT). XPCT enables to map the distribution of Aβ plaques in the whole excised brain without labeling. In this work we describe a unique collection of four transgenic models of AD, together with a human sporadic and a rare genetic case of AD, thus exploring the full spectrum of amyloid contrast in XPCT.

Identifiants

pubmed: 37574159
pii: S1742-7061(23)00438-5
doi: 10.1016/j.actbio.2023.07.046
pii:
doi:

Substances chimiques

Trace Elements 0
Copper 789U1901C5
Amyloid beta-Peptides 0
Metals 0
Zinc J41CSQ7QDS
Iron E1UOL152H7
Amyloid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

260-272

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Matthieu Chourrout (M)

Univ. Lyon, Lyon Neuroscience Research Center (CRNL); CNRS UMR5292; INSERM U1028, Univ. Lyon 1, Lyon, France.

Christophe Sandt (C)

Synchrotron SOLEIL, Saint-Aubin, France.

Timm Weitkamp (T)

Synchrotron SOLEIL, Saint-Aubin, France.

Tanja Dučić (T)

ALBA-CELLS Synchrotron, MIRAS Beamline, Cerdanyola del Vallès, Spain.

David Meyronet (D)

Hospices Civils de Lyon, Neuropathology Department, Lyon, France; Univ. Lyon, Cancer Research Center of Lyon (CRCL); INSERM U1052; CNRS UMR5286, Univ. Lyon 1; Centre Léon Bérard, Lyon, France.

Thierry Baron (T)

Univ. Lyon, ANSES, Lyon, France.

Jan Klohs (J)

ETH Zurich, Institute for Biomedical Engineering, Zurich, Switzerland.

Nicolas Rama (N)

Univ. Lyon, Cancer Research Center of Lyon (CRCL); INSERM U1052; CNRS UMR5286, Univ. Lyon 1; Centre Léon Bérard, Lyon, France.

Hervé Boutin (H)

Univ. Manchester, Faculty of Biology Medicine and Health, Wolfson Molecular Imaging Centre, Manchester, United Kingdom.

Shifali Singh (S)

Univ. Grenoble Alpes, Synchrotron Radiation for Biomedicine (STROBE); Inserm UA7, Grenoble, France.

Cécile Olivier (C)

Univ. Grenoble Alpes, Synchrotron Radiation for Biomedicine (STROBE); Inserm UA7, Grenoble, France.

Marlène Wiart (M)

Univ. Lyon, CarMeN Laboratory; INSERM U1060, INRA U1397, INSA Lyon, Univ. Lyon 1, Lyon, France; CNRS, France.

Emmanuel Brun (E)

Univ. Grenoble Alpes, Synchrotron Radiation for Biomedicine (STROBE); Inserm UA7, Grenoble, France.

Sylvain Bohic (S)

Univ. Grenoble Alpes, Synchrotron Radiation for Biomedicine (STROBE); Inserm UA7, Grenoble, France.

Fabien Chauveau (F)

Univ. Lyon, Lyon Neuroscience Research Center (CRNL); CNRS UMR5292; INSERM U1028, Univ. Lyon 1, Lyon, France; CNRS, France. Electronic address: chauveau@cermep.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH